All cancer mutations that cause drug resistance fall into one of four categories. New research has detailed each type, helping to uncover targets for drug development and identify potential effective ...
Vertex's diverse pipeline positions it for a growth, despite challenges in launching new drugs like Casgevy and suzetrigine.
Intellia Therapeutics' innovative gene editing technology could revolutionize medicine, but investors need a strong stomach ...
BMO Capital analyst Kostas Biliouris maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) today and set a price ...
We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going ...
A collaborative effort between investigators at the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) and Massachusetts General Hospital (MGH), a founding ...
Because sickle cell disease isn’t as progressive a disease as others that have gene therapies available, there isn’t as much ...
Our current food system is facing a myriad of critical challenges. The United Nations predicts that the world population will ...
2d
In a potential advance for melanoma patients, researchers at ChristianaCare's Gene Editing Institute have used CRISPR gene ...
This diverse set of growth stocks offers tremendous opportunities in the fields of AI, space, biotech, and emerging ...
In an assessment of 9 clinics and 166 users spanning from nurses, medical assistants, and advanced practice clinicians to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback